Rabusertib

DB11662InvestigationalSmall molecule

Rabusertib has been used in trials studying the treatment of Cancer, Solid Tumors, Advanced Cancer, Pancreatic Neoplasms, and Non Small Cell Lung Cancer.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase Chk1
Curator reviewed
Formula / weight: C₁₈H₂₂BrN₅O₃ · 436.31 g/mol (avg)
Code names: IC-83 · LY-2603618

Resolves to

Compound

UNII3S9L1NU6U7CAS911222-45-2ChEMBLCHEMBL3039517ChEBI124917PubChem11955855

Structure

InChIKeySYYBDNPGDKKJDU-ZDUSSCGKSA-NSMILESCC1=NC=C(NC(=O)NC2=C(OC[C@@H]3CNCCO3)C=C(C)C(Br)=C2)N=C1

Targets

O14757CHEK1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rabusertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account